INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

Targeting Tumor Microenvironment in Pancreatic Cancer: A Translational Approach

Sukhpreet Kaur*, Gurpreet Kaur, Tanveer Ahmad, Nisha

School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab, India.

ARTICLE INFO

Published: 02 May 2026
Keywords:
Malignancy, pancreatic ductal adenocarcinoma (PDAC),tumor Microenvironment (TME),anti-Tumor ,immunetherapy ,chemotherapy.
DOI:
10.5281/zenodo.19983775

ABSTRACT

Pancreatic cancer is a highly aggressive malignancy with a poor prognosis primarily due to late diagnosis and ineffective therapies. Despite advancements in molecular oncology, survival rates remain stagnant, highlighting the necessity for new treatment avenues. A characteristic feature of pancreatic ductal adenocarcinoma (PDAC) is its desmoplastic tumor microenvironment (TME), which comprises diverse cellular and acellular elements that promote tumor growth, metastasis, and therapy resistance. This immunosuppressive and fibrotic niche complicates drug delivery and hinders anti-tumor responses. Current research focuses on strategies to remodel the TME to enhance therapeutic responses, including targeting stromal signaling pathways and combining TME-guided therapies with immunotherapy and chemotherapy. Clinical studies of agents like CXCR4-inhibitors and hyaluronidase have shown initial promise, though the TME's heterogeneity remains a barrier. The review emphasizes the importance of understanding the pancreatic TME biology to identify therapeutic targets and improve patient outcomes, advocating for interdisciplinary collaboration between basic science and clinical research.

INTRODUCTION

Pancreatic cancer (PC), i.e., pancreatic ductal adenocarcinoma (PDAC), is one of the most aggressive and deadly cancers worldwide, it occupies position 7 among cancer-related causes of death, whereas its prognosis is not any better since the mortality rate of PDAC patients does not exceed 12%. The source of this high lethality is the later clinical manifestation of the disease, massive metastatic nature and massive resistance to chemotherapy, radiotherapy, and immunotherapy. Unlike most other solid neoplasms, PDAC has a characteristic histopathological structure, in which a dense network of desmoplastic stroma represents one of the key components of tumor microenvironment (TME) [1].

The pancreatic TME is a complex dynamic environment that includes cancerassociated

***Corresponding Author:** Sukhpreet Kaur
Address: *School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab, India*
Email : sukhchehal789012@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

fibroblasts (CAFs), pancreatic stellate cells (PSCs), immune suppressive myeloid and lymphoid cells, extracellular matrix (ECM) components and abnormal vascular network. It does not only provide structural scaffolding, but also actively promotes tumour progression by promoting fibrosis and inhibition of immune mediated tumor elimination by inflammation. This unregulated deposition of these ECM and a hyper activation of the stromal components create a physical and bio chemo barrier preventing good delivery of drugs and providing therapeutic resistance[2].

Recent data suggests that TME-malignant cell interactions are a two-way process that is vital in tumor maintenance. Therefore, the regulation of stromal and immune TME constituents has become one of the potential therapeutic targets. Translational approaches, which are intended to moderate TME (depletion of stromal cells, remodeling of ECM, and immune reprogramming), are even intended to enhance drug delivery as well as sensitize tumors to traditional and neo-targeted therapies, with the goal of improving the curative outlook of this potential otherwise inexorable disease[3].

2. Tumor Microenvironment in Pancreatic Cancer

Tumor microenvironment (TME) of pancreatic ductal adenocarcinoma comprises a highly complex environment, both cellular and acellular and constitutes dynamic interactions between it and malignant cells. The complex system has an extensive effect on tumourigenesis, metastatic spread and resistance to therapy, making it an essential hub of interest in oncology studies[4].The stromal compartment is one of the hallmarks of the pancreatic TME. Cancer-related fibroblasts (CAFs), and pancreatic stellate cells (PSCs) become the main stromal components, which are responsible for the large-scale extracellular matrix (ECM) production[5]. The resultant effect of their activation is fibrotic remodelling and increase of tumour stiffness, which hamper the delivery of the chemotherapeutic agents to the tissues through the vascular system. This reciprocal crosstalk between the stromal cells and the cancer cells enhances tumour proliferation, invasion and provides a permissive environment that supports invasion by metastasis[6].

The pancreatic tumour microenvironment is defined by an excessive condition of immunosuppression. It is mostly colonized by tumour-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs) as well as by regulatory T cells (Tregs). Cytotoxic T -cell activity is blocked by these populations to reduce antitumour immunity and promote immune tolerance. As a result, pancreatic tumours often avoid immune surveillance and that is why it is one of the reasons the modern immunotherapeutic approaches have limited effect on this malignancy[7].Pancreatic tumour vascular characteristics are characterized by being hypovascular and disorganized. Poor perfusion will create hypoxic niches which precondition tumour aggressiveness and reprogramming of metabolism. Hypoxic microenvironment also increases angiogenic, epithelial 0 -mesenchymal transition and resistance against conventional modalities signalling cascades[8].The extracellular matrix compounds therapeutic issues by having a dense and fibrotic structure. It is not only a mechanical barrier to diffusions of drugs, but also a biological framework that induces cellular motility and invasion[9]. The complex interaction of stromal, immune, vascular, and matrix makes up an unfavorable but conducive environment which drives the progression of pancreatic cancer. To this end, selective

manipulation of the TME has a significant potential in improving therapeutic outcome against this very deadly ailment[10].

3. Cellular and Molecular tumor microenvironment Players in Pancreatic Cancer.

PDAC Tumor microenvironment (TME) is an extremely complex but dynamic system composed of various components of cells and molecules that have complicated interactions with malignant cells. Such interactions affect tumor development, resistance to treatment, and finally clinical results are achieved. To develop specific therapeutic measures, it is necessary to have a detailed knowledge of the cellular and molecular components of the TME.Cellular elements of the Pancreatic TME are given below[11].

3.1Fibroblasts in cancer and pathophysiology: Cancer-Associated Fibroblasts (CAFs):

CAFs are one of the richest stromal cell types in PDAC and contribute to the prominent fibrotic reaction witnessed in this cancer type. They produce structural proteins advancing growth (collagen and fibronectin) as well as cytokines and growth factors that maintain the growth of the tumor[12]. CAFs are heterogenous, and they contain different subpopulations that have different functional roles. Some of the subtypes facilitate tumor progression and invasion and immune suppression whereas others can restrain tumor growth by imposing mechanical support or paracrine signaling. This duality has some therapeutic prospects and challenges[13].

3.2 Independent cell types: Pancreatic Stellate Cells (PSCs):

PSCs in their dormant condition preserve a normal pancreatic structure. When stimulated by inflammatory stimuli or tumor-associated stimuli, they become myofibroblast-like cells, which hyperproduce extracellular matrix (ECM) components causing the phenomenon of desmoplasia a characteristic of PDAC[14]. The process makes tissues stiffer and vascularization inhibited. PSCs also secrete growth factors and cytokines that promote tumor growth, migration as well as chemoresistance.Here, a distinctive alteration in the clinical efficacy of chemotherapy and radiotherapy has been proposed, resulting from the natural alteration of macrophages into Tumor-Associated Macrophages (TAMs).: TAMs present a significant immune part of the TME and are concentrated towards the M2 type which favours tumorgrowth[15]. M2 macrophages release the pro-angiogenic and immunosuppressive determining factors that enhance metastasis and suppress good T- cells reaction. Poor prognosis is associated with a large number of TAMs and myocardial infarction, which is why they are important potential therapeutic targets[16].

3.3 Myeloid -Derived Suppressive Cells (MDSCs):

MDSCs have a central role to play in suppressing antitumor immunity. They inhibit T-cell activation with the synthesis of arginase and reactive oxygen species and thus they regulate immune evasion by the tumor. Their proliferation in the microenvironment of the PDAC also complicates the strategies of immunotherapy[17].Endothelial Cells: No erythematous changes observed at `stage.|human|Vasculature: No erythematous changes seen at this point. The PDAC blood supply is characterized by a significant irregularity and inadequacy, which play a role in the development of hypoxia, acidosis, and drug delivery limitations[18]. Abnormal endothelial cues impart ineffective perfusion; consequently,

this triggers adaptive survival mechanisms in the tumor cells, and it leads to aggressive characteristics and tolerance to chemotherapy and radiotherapy[19].

3.4 TME Molecular Mediators of TME Function.

Major molecular mediators coordinate the tumor cells with properties of TME. The factors that influence growth and activation of fibrosis, angiogenesis, and immune modulation involve transforming growth factor -b (TGF -b) and vascular endothelial growth factor (VEGF)[20]. The immunosuppressive milieu is further supported by the cytokines such as interleukin-6(IL-6) and interleukin-10 (IL-10). There is an attraction of cancer cells to immune and stromal cells assisted by chemokines like CXCL12 which promotes the survival and proliferation of cancer cells. Additionally, matrix metalloproteinases (MMPs) reorganize the ECM simulating the invasion and the biochemical environment of the TME[21].

The interaction between CAFs, PSCs, immune cells, endothelial elements, and a sophisticated molecular network in their complex interplay is the basis of the pancreatic TME. The understanding of these communications is also necessary in creating new, combination-based therapies to interfere with tumor stroma crosstalk and enhance patient outcomes in pancreatic cancer[22].

4. Targeting Tumor Microenvironment: Preclinical Advances

Attack on tumor microenvironment (TME) is an approach that has been developed as one of the promising options in overcoming therapeutic resistance and improving cancer treatment results. The thick extracellular matrix (ECM) of tumors is a mechanical barrier to drug delivery; as such strategies to overcome this has led to the development of stromal ablation therapies to counteract the barrier[23]. Hyaluronic acid can be degraded by hyaluronidase and PEGylated hyaluronic acid PEGPH20 in particular, which leads to a decrease in pressure in the interstitial fluid and an increase in vascular perfusion[24]. This remodelling enhances the effectiveness of chemotherapeutic agents by supporting the efficient delivery of chemotherapeutic agents. Likewise, the anti-fibrotic drugs like pirfenidone and losartam weaken fibrosis through suppressing the activation of fibroblasts and the deposition of collagen which normalizes the ECM and enhances the diffusion of drugs within tumour tissue[25].

Another important aspect of TME modulation is that of vascular normalization. Tumour vasculature has often been characterized by lack of structure, leakage and ineffectiveness, resulting in hypoxia and limited delivery of therapeutic factors. Transient restoration of vessel architecture and functioning with anti-angiogenic interventions in antagonism of the vascular endothelial growth factor (VEGF) signalling pathway[26]. This normalisation increases oxygen and nutrient penetration as well as facilitating drug penetration. Overall, though, those progresses in preclinical research of stromal depletion, anti-fibrotic treatment practices and vascular normalisation underline the importance of TME-targeted approaches in overcoming drug resistance and in enhancing the actions of traditional or new anti-cancer drugs[27].

4.1 Immune Microenvironment Modulation

Dynamics of the immune microenvironment are one of the key areas of study in regards to pancreatic ductal adenocarcinoma (PDAC) as the tumour exhibits an immunosuppressive environment that thus hinders effective antitumour

responses.PDAC has shown limited response to checkpoint blockade agents targeting PD-1, PD-L1 and CTLA-4 but responses can be explained within the context of a low tumour mutational burden, insufficient tumour-immune-cell infiltration and a dense stromal compartment with a restraining ability on immune activation[28]. Modern research strives to enhance the treatment effect of these inhibitors with a combination of chemotherapy, radiotherapy, or stromal-directed agent. Examples of cancer vaccines under development include GVAX and CRS 207 used as remodelling agents of the tumour microenvironment and inducing potent immune responses[29]. GVAX uses irradiated tumour cells that express granulocyte -macrophage colony -stimulating factor (GM -CSF) to enhance antigen presentation and T -cell activation, and CRS -207 uses a live attenuated -Listeria monocytogenes -vector that expresses mesothelin in order to enhance cytotoxic T -cell activity[30].

The overall goal of these interventions is to first convert the immunologically cold PDAC tumour into a hot phenotype by refilling and mediating effector T cells. Among other adoptive cell therapies, which are of current preclinical and clinical interest, are chimeric antigen receptor (CAR) -T cells and tumour-infiltrating lymphocyte (TIL) Strategies. These modalities have so far shown moderate efficacy, but when combined with tumour stroma remodelling or immune-cells trafficking agents, show promise and revitalizes hope of immunotherapeutic efforts in PDAC[31].

4.2 Nanomedicine Approaches

Nanomedicine could be used to powerfully address the stromal and vascular barriers of tumor microenvironment (TME) to increase therapeutic delivery and effectiveness. Nanoparticles may be designed in a manner to enhance the diffusion of anticancer drugs into the thickened extracellular matrix, and targeted drug release at the tumorlocation[32]. These nanoscale systems allow the controlled delivery of drugs, prolonged times of circulation and a decrease in off-target toxicity. It is also possible to prepare functionalized nanoparticles to react to a set of tumor-associated signals, including pH, enzymatic activity, or hypoxia to release their payload selectively in the TME[33]. Liposomes, polymeric nanoparticles and micelles are examples of nanocarriers which have been shown to be useful in the delivery of chemotherapeutic agents in pancreatic cancer and other desmoplastic tumors with minimal systemic side effects[34].

Table 1: Major Cellular and Molecular Components of TME in Pancreatic Cancer and Their Roles

Component	Role in Tumor Progression	Reference no
CAFs	Extracellular deposition, fibrosis, cytokine release and drug resistance.	[35]
PSCs	There is promotion of desmoplasia and increase in growth of the tumor.	[36]
TAMs	Angiogenesis, immunosuppression, and metastasis.	[37]
ECM	Mechanical impediments to drug delivery and tumor invasion.	[38]
Hypoxia	Encouragement of epithelial-to-mesenchymal transition and metastasis.	[39]

5. Translatoral and Clinical Developments.

In the last ten years, translational oncology has made significant contributions to our understanding of the pancreatic tumor microenvironment (TME) and its impact on the

therapeutic outcome. In pancreatic ductal adenocarcinoma (PDAC) desmoplasia, aberrant vascular architecture, and a strong level of immunosuppression characterize the TME and impede drug delivery into cancer cells and anti-tumor immune response[40]. Translational studies have attempted to be able to translate preclinical findings on stromal and vascular dynamics into clinical modalities that are able to overcome these barriers. Scientists have studied the relationship between tumor stroma, immune components and vascular integrity to come up with combination therapies that are able to attack the malignant cells and their supportive milieu[41]. These efforts balance both laboratory findings and clinical treatments thus leading to an integrative treatment paradigm. The subsequent clinical trials efforts have led to subjects of stromal modulation, immunotherapeutic treatments, and vascular normalization, as potentially effective approaches to improve survival and response to treatment in patients with PDAC[42].

5.1 TME-Targeted Clinical Trials

The therapeutic use of TME-based approaches has produced numerous clinical trials which have tried to manipulate the stromal components, normalization of tumor vasculature, and the enhancement of the anti-tumor immunity to a greater extent[43]. Since PDAC is resistant to traditional cytotoxic therapy, TME-based component targeting has become an important adjunct therapy. Stromal depletion or remodeling trials instead of hyaluronidase-based enzymes have also tried to reduce tumoral interstitial pressure and increase the penetration of drugs. Similarly, the process of normalizing vascular phenotype is meant to restore effective perfusion and thus increasing chemotherapeutic potency and oxygen delivery[44]. The monotherapy of immune checkpoint blockade has not been associated with significant effect in PDAC because of immune exclusion of stroma mediated by TME; nonetheless, combinatorical studies of stroma- and vessel-modulating mediators are currently being pursued[45].

5.1.1 PEGPH20

PEGPH20 is a pegylated recombinant hyaluronidase-derived hyaluronan (HA) polymer, which is better positioned to break down the hyaluronic acid polymer (HA) that is also responsible in PDAC to raise intrastitial pressure and cause inadequate vascular perfusion. Initial pilot trials showed PEGPH20 used together with conventional chemotherapy agents, including nab -paclitaxel and gemcitabine, had a significant additive effect on progression-free survival in patients with HA -high tumors, suggesting a biomarker-based advantage. PEGPH20 breaks down HA, which leads to the physical barrier of the malignant cells being broken, allowing drugs to enter the tumor bed and oxygenation to occur more easily[46]. Later phase-III trials however gave mixed results with certain subpopulations of patients benefiting and others developing increased toxicity and thrombo-embolic events. The findings support the heterogeneity of the stromal targeting and the inherent heterogeneity of PDAC stroma[47].

5.1.2 Losartan

Angiotensin-II receptor antagonist Losartan, traditionally used as a hypertension drug, has been suggested to be used as a stromal-modifying and vascular-normalizing agent in PDAC. Its suggested mechanism involves the reduction of collagen and hyaluronan production by the cancer-related fibroblasts thus reducing the stiffness of the extracellular matrix and interstitial fluid pressure[48]. The effect of this remodeling increases perfusion as well as helps deliver

chemotherapeutic agents better into the tumoral core. The preclinical models have demonstrated that losartan can be used in synergy with chemotherapy and radiotherapy by increasing the concentration of drugs and oxygen level intra tumor[49]. Losartan has also been tested in clinical practice with standard chemotherapy in the management of a locally advanced PDAC with promising results of response and resectability[50].

5.1.3 Checkpoint Blockade

Although immune checkpoint inhibitors (ICIs) have been shown to have a transformative success in multiple malignancies, their application in PDAC has had a low response. The TME associated with immunosuppressive reaction, which is characterized by the exclusion of cytotoxic T cells, infiltration of regulatory T cells, and preeminence of myeloid-derived suppressive cells make PDAC highly resistant to single-agent ICI therapy[51]. It has been explored in clinical trials that incorporation of ICIs with any of the previously listed therapies as well as oncolytic virus and stromal modulators can be used to enhance immune infiltration and activation[52]. The most promising ones are to combine PD-1 /PD-L1 blockers with agents that can interfere with the stromal barrier or normalise vasculature to allow an increase in immune cell penetration. On-going research is also focused on the identification of predictive biomarkers, including but not limited to microsatellite instability, tumor mutational burden, and immune signature to assist patient selection[53]. The attempts are a significant step to achieving effective immunotherapy of PDAC by redefining the immune contexture and neutralizing the suppressive effects of TME[54].

5.2 Combination Therapies.

Combinations of tumor microenvironment (TME)-targeted therapy with standard therapeutic systems such as chemotherapy, radiotherapy and immunotherapy have been shown to enhance antitumor properties in pancreatic ductal adenocarcinoma (PDAC). The presence of desmoplastic stroma, deviant vasculature, and immunosuppressive milieu that is typical of PDAC poses considerable challenges to drug delivery and immune infiltration, thus making monotherapies to be of little use[55]. With the use of TME-modulating drugs, these deterrents can be reduced and allow standard therapeutic regimens to increase their penetration and activity. Indicatively, stromal depletion through hyaluronan or collagen targeting agents reduces interstitial pressure which in turn increases perfusion of chemotherapeutic agents including gemcitabine and nab-paclitaxel[56]. Similarly, vascular normalization drugs like losartan enhance the tissue oxygenation and radiosensitivity, and hence maximize the outcomes of radiotherapies[57].

At the same time, mutually energizing immune checkpoint inhibitors with stroma-neutralizing or angiogenesis-neutralizing signs delivering a bombarding evidence of crucial case in preclinical efforts and preclinical studies. The aim of these regimens is to re-establish the inherently immunologically cold PDAC microenvironment to a more inflamed or hot phenotype which the immune can be activated[58]. In addition, the combination of cytotoxic and immunotherapeutic treatments allow inducing immunogenic cell death, which promotes long-term antitumor immune responses. The critical role of the strategic sequencing of therapeutic interventions is also present; pretreatment by stromal modifiers may create temporal windows, which increase the perfusion and immune accessibility[59].Altogether, the combination

therapies to be used simultaneously to address the tumor mass and reestablish its microenvironment present a reasonable and promising approach to overcoming the intrinsic resistance to therapeutic agents in PDAC. Clinical studies are an ongoing process that is still polishing these combination regimens and there is a current emphasis on biomarker guided individualisation that aims at maximising the synergistic therapeutic effects and reducing the toxicity associated with treatment[60].

5.3 Biomarkers

Biomarkers have to be reliable to be able to refine the tumour microenvironment (TME)-targeted therapeutics and improve clinical outcomes in pancreatic ductal adenocarcinoma (PDAC). The inherent biological heterogeneity of PDAC, combined with its complexity of the microenvironment, does not allow a monolithic effect of the therapy in all patients[61]. This has led to the intensive studies of novel markers like circulating tumour DNA (ctDNA), stromal signatures and immune profiling to guide selection of therapy, as well as to monitor response to therapy and disease persistence in the aftermath of treatment.tDNA is a non-invasive real-time surrogate of tumour dynamics that can be used to predict resistance and disease progression, and also to detect residual disease after therapy. In addition, change in ctDNA amounts can predict treatment efficacy before radiologic changes appear[62].

Markers of the stroma and extracellular matrix (ECM) including the level of hyaluronan, collagen density, and fibroblast activation markers are under consideration as predictive markers of stroma responsiveness to stromal targeted agents such as PEGPH20 or losartan[63]. The patients reported to have strong stromal rigidity or hyaluronan-containing tumours can receive increased benefit of TME-modulating interventions. Moreover, immune profiling of TME, such as the counting of tumour-infiltrating lymphocytes, myeloid-derived suppressor cells, and cytokine expression patterns, can be used to determine patient subsets that might be hyper responsive to immunotherapy or a combination of immunotherapy[64]. The combination of these biomarker analyses supplements individualized treatment plans and allows the tailoring of treatment to be dynamic. With the potential for future trials that would prove these indicators, precision targeted TME presents a daunting future of revolutionizing the treatment of PDAC and therefore making it no longer a homogenous and one-size-fits-all paradigm, but rather a biomarker-driven, patient-centered treatment paradigm[65].

Table 2: Selected Clinical Trials Targeting TME in Pancreatic Cancer

Strategy	Agent/ Approaches	Clinical outcome	Reference
Stromal depletion	PEGPH20+ gemcitabine/ nab-paclitaxel.	Better PFS with HA-high patients, less benefit OS.	[66]
Anti - Fibrotic	Losartan+ FOLFIRINOX	Better response and administration of drugs.	[67]
Immune Modulation	GVAX + CRS-207	Improved immune response, modicum survival.	[68]
Checkpoint inhibitors	Nivolumab, Pembrolizumab	Monotherapy as an agent of limited activity.	]69]
Nano medicine	Nab-paclitaxel (Abraxane)	Better survival in combination therapy.	[70]

6. Challenges in Targeting TME

The attempts to therapeutically regulate the tumor microenvironment (TME) in pancreatic ductal adenocarcinoma (PDAC) have shown that there are severe problems that limit a steady clinical achievement. One of the major barriers is heterogeneity of tumors[71]. There is a great deal of variability in stromal makeup, density of the extracellular matrix, and immune cell infiltration among different patients and among different tumor compartments within PDAC-TME[72]. This heterogeneity brings about unpredictable reaction to stromal or immunomodulatory treatment, and thus, makes it difficult to produce universally effective treatment frameworks. A profound knowledge of patient-specific TME profiles through sophisticated molecular and imaging studies is hence required so as to attain individual therapeutic response[73].

Another issue of concern is adaptive resistance. The compensatory signal transduction pathways are often activated by the malignant tumor in reaction to the depletion of stroma or normalization of the vascular network. Indicatively, blocking any one of the stromal components, hyaluronan, could trigger increased fibrosis or influx of immunosuppressive cells and finally restore a conducive tumorniche[74]. These dynamic therapeutic responses require combination regimens and dynamic therapeutic changes in order to prevent relapse. The barrier to drug delivery remains to be a characteristic barrier in PDAC therapy. The thickness of the extra-cellular matrix (ECM) and disorganized vasculature in the TME limit perfusion, diffusion of nutrients, and the diffusion of chemotherapeutic/immunotherapeutic agents into the malignant cells[75]. In cases where the stromal-targeting agents can generate partial decompression, the distribution of drugs is often non-uniform because of the fact that the remodeling of the ECM is not complete and there are hypovascular domains remaining. The problem of safety and toxicity also makes TME targeting more complicated. A number of preclinical and clinical studies have suggested that the excessive loss of stroma has the ability to neutralise the restraining factors that naturally inhibit tumor development, which may result in a more aggressive phenotype[76].

7. Future Directions

The promotion of therapeutics to pancreatic ductal adenocarcinoma (PDAC) requires the incorporation of personalized and technologically advanced approaches to characterize and attack the tumor microenvironment (TME). Personalized treatment plans based on the stratifications of patients based on stromal constitution, immune infiltration and molecular signatures can support a more specific choice of TME-specific agents. The biomarker-based paradigms will also yield to the situation of each patient receiving interventions tailored to their unique tumor milieuts.

Organoid and ex vivo systems are becoming useful resources that can be used to interrogate the dynamics of the TME in controlled settings. With these displaying patient acquired constructs to the patient, they maintain cellular and stromal complexity thus allowing massive-scale pharmacologic screening and real-time measurement of therapeutic reactions. Simultaneously on the same note, single-cell and spatial transcriptomic technologies can provide the resolutions to define the heterogeneity of cells and cellular communication like never before in the TME, thus, enabling the discovery of new targets and understanding resistance mechanisms.

Future plans will probably focus on using combinatorical strategies that entail the use of

stromal, vascular, and immune factors to achieve synergetic effects and overcome multidimensional defenses of PDAC. The systems biology and artificial intelligence are expected to have transformative power allowing predicting treatment courses and optimizing multi-agent therapy settings. All these developments are promising a high level of refinements in precision medicine in PDAC, improvement of therapeutic effects, and future development of long-term, personalized control of the disease.

CONCLUSION

In pancreatic ductal adenocarcinoma (PDAC), the microenvironment in the pancreatic tumor (PTA) continues to be a major discretion of resistance to therapy and progression of the disease. Its thick stroma, malparediculous vasculature, and immunosuppressive cellular net are a physical/biological barrier which obstructs drug delivery, and immunosuppressive effects. However, the TME is also an encouraging source of innovation in therapy. Early trials of translational and clinical studies involving the modulation of stromal components, normalization of vascular architecture and re-programming immune dynamics give positive results. Nevertheless, the inherent heterogeneity of PDAC and its adaptive resistance still pose a barrier to the consistent efficacy of PDAC across patients. Advances in molecular profiling, biomarker identification and real-time monitoring systems are bringing in a new age of personalized medicine, which allows the stratification of patients, using stromal and immune signatures. These strategies have the potential to point at individuals who are most likely to experience a positive impact of TME-targeted interventions with limited unnecessary toxicity. The introduction of the next-generation technologies, such as single-cell and spatial transcriptomics, organoid systems, and artificial intelligence, widen our understanding of the complexity of TME and their responsiveness to therapy. The next generation PDAC treatment will be based on the combination regimens of rationally design, and precision-based, which will target both tumor cell survival and microenvironmental support system at the same time. A paradigm shift whereby the cancer and the ecosystem are targeted together may completely change the way therapeutic outcomes are achieved wherein PDAC may be seen as intractable malignancy, but instead an illness that can be better addressed using synergistic and tailored therapeutic approaches.

REFERENCES

1. Jiménez, Diego J., et al. "Clinical and preclinical targeting of oncogenic pathways in PDAC: targeted therapeutic approaches for the deadliest cancer." International journal of molecular sciences 25.5 (2024): 2860.
2. Truong, Linh-Huyen, and SiimPauklin. "Pancreatic cancer microenvironment and cellular composition: current understandings and therapeutic approaches." Cancers 13.19 (2021): 5028.
3. Wu, B., Shi, X., Jiang, M., & Liu, H. (2023). Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment. Molecular Cancer, 22(1), 38.
4. Tufail, M., Hu, J. J., Liang, J., He, C. Y., Wan, W. D., Huang, Y. Q., ... & Li, N. (2024). Hallmarks of cancer resistance. Iscience, 27(6).
5. Hessmann, E., Buchholz, S. M., Demir, I. E., Singh, S. K., Gress, T. M., Ellenrieder, V., &Neesse, A. (2020). Microenvironmental determinants of pancreatic cancer. Physiological reviews.

6. Link, W., Ilardi, G., &Zannetti, A. (2021). Tumor microenvironment: molecular mechanisms and signaling pathways involved in metastatic progression. Frontiers in Oncology, 11, 730815.
7. Fan, J. Q., Wang, M. F., Chen, H. L., Shang, D., Das, J. K., & Song, J. (2020). Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma. Molecular cancer, 19(1), 32.
8. Sharma, R., &Malviya, R. (2024). Modifying the electrical, optical, and magnetic properties of cancer cells: A comprehensive approach for cancer management. Medicine Advances, 2(1), 3-19.
9. Mierke, C. T. (2020). Mechanical cues affect migration and invasion of cells from three different directions. Frontiers in cell and developmental biology, 8, 583226.
10. Berdiaki, A., Neagu, M., Tzanakakis, P., Spyridaki, I., Pérez, S., &Nikitovic, D. (2024). Extracellular matrix components and mechanosensing pathways in health and disease. Biomolecules, 14(9), 1186.
11. Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X. Y. (2024). Exploring treatment options in cancer: tumor treatment strategies. Signal transduction and targeted therapy, 9(1), 175.
12. Bryce, A. S., Dreyer, S. B., Froeling, F. E., & Chang, D. K. (2022). Exploring the biology of cancer-associated fibroblasts in pancreatic cancer. Cancers, 14(21), 5302.
13. Badran, O., Cohen, I., & Bar-Sela, G. (2025). Cancer-Associated Fibroblasts in Solid Tumors and Sarcomas: Heterogeneity, Function, and Therapeutic Implications. Cells, 14(17), 1398.
14. Wang, Z., Dong, S., & Zhou, W. (2024). Pancreatic stellate cells: Key players in pancreatic health and diseases. Molecular Medicine Reports, 30(1), 109.
15. Malfitano, A. M., Pisanti, S., Napolitano, F., Di Somma, S., Martinelli, R., &Portella, G. (2020). Tumor-associated macrophage status in cancer treatment. Cancers, 12(7), 1987.
16. Prouse, T., Majumder, S., &Majumder, R. (2024). Functions of TAM receptors and ligands Protein S and Gas6 in atherosclerosis and cardiovascular disease. International Journal of Molecular Sciences, 25(23), 12736.
17. Saka, D., Gökalp, M., Piyade, B., Cevik, N. C., Arik Sever, E., Unutmaz, D., ...&Asimgil, H. (2020). Mechanisms of T-cell exhaustion in pancreatic cancer. Cancers, 12(8), 2274.
18. Mori, L., Basta, B., Vailati, D., Bonvecchio, E., & Marino, G. (2024). National Congress.
19. Obeagu, E. I. (2025). BREAST CANCER CELLS UNDER OXYGEN STRESS: ADAPTATION AND SURVIVAL MECHANISMS. Universal Journal of Pharmaceutical Research.
20. Murugan, N. J., Cariba, S., Abeygunawardena, S., Rouleau, N., & Payne, S. L. (2024). Biophysical control of plasticity and patterning in regeneration and cancer. Cellular and Molecular Life Sciences, 81(1), 9.
21. Atreya, I., &Neurath, M. F. (2022). How the tumormicromilieu modulates the recruitment and activation of colorectal cancer-infiltrating lymphocytes. Biomedicines, 10(11), 2940.
22. Truong, L. H., &Pauklin, S. (2021). Pancreatic cancer microenvironment and cellular composition: current understandings and therapeutic approaches. Cancers, 13(19), 5028.
23. Zhang, M., Chen, Y., Li, Y., Zhao, Y., Lv, B., Cao, J., ...& Cong, H. (2025). Manipulating extracellular matrix to enhance intratumor drug delivery for nanomaterial-based photothermal therapy. Chinese Chemical Letters, 111588.

24. Lierova, A., Kasparova, J., Filipova, A., Cizkova, J., Pekarova, L., Korecka, L., ...&Sinkorova, Z. (2022). Hyaluronic acid: known for almost a century, but still in vogue. Pharmaceutics, 14(4), 838.
25. Cassani, M., Fernandes, S., Pagliari, S., Cavalieri, F., Caruso, F., & Forte, G. (2025). Unraveling the role of the tumor extracellular matrix to inform nanoparticle design for nanomedicine. Advanced Science, 12(2), 2409898.
26. Mortezaee, K. (2021). Normalization in tumor ecosystem: Opportunities and challenges. Cell Biology International, 45(10), 2017-2030.
27. Torna, S., Gkretsi, V., &Stylianou, A. (2025). Photodynamic Therapy and Tumor Microenvironment-Targeting Strategies: A Novel Synergy at the Frontier of Cancer Treatment. International Journal of Molecular Sciences, 26(17), 8588.
28. Simms, N. (2023). Investigating the crosstalk between hepatic stellate cells and antigen presenting cells in pancreatic cancer liver metastases (Doctoral dissertation, University of Liverpool).
29. Liu, J., Fu, M., Wang, M., Wan, D., Wei, Y., & Wei, X. (2022). Cancer vaccines as promising immuno-therapeutics: platforms and current progress. Journal of Hematology& Oncology, 15(1), 28.
30. Liu, T. W. (2023). Myeloid-Derived Suppressor Cells Expressing Myeloperoxidase Directly Inhibit Adaptive Immune Cells Limiting Immunotherapy in Melanoma.
31. Barros Ferreira, A. G. (2023). Restoring antitumor immunity with dendritic cell reprogramming strategies. Reprogramming cancer cells to antigen-presenting cells (Doctoral dissertation, Lund University).
32. Munir, M. U. (2022). Nanomedicine penetration to tumor: challenges, and advanced strategies to tackle this issue. Cancers, 14(12), 2904.
33. Peng, S., Xiao, F., Chen, M., &Gao, H. (2022). Tumor-microenvironment-responsive nanomedicine for enhanced cancer immunotherapy. Advanced Science, 9(1), 2103836.
34. Slapak, E. J., El Mandili, M., Bijlsma, M. F., &Spek, C. A. (2022). Mesoporous silica nanoparticle-based drug delivery systems for the treatment of pancreatic cancer: a systematic literature overview. Pharmaceutics, 14(2), 390.
35. Feng, B., Wu, J., Shen, B., Jiang, F., & Feng, J. (2022). Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures. Cancer Cell International, 22(1), 166.
36. Nandi, T., Pradyuth, S., Singh, A. K., Chitkara, D., & Mittal, A. (2020). Therapeutic agents for targeting desmoplasia: current status and emerging trends. Drug Discovery Today, 25(11), 2046-2055.
37. Ghebremedhin, A., Athavale, D., Zhang, Y., Yao, X., Balch, C., & Song, S. (2024). Tumor-associated macrophages as major immunosuppressive cells in the tumor microenvironment. Cancers, 16(19), 3410.
38. Henke, E., Nandigama, R., &Ergün, S. (2020). Extracellular matrix in the tumor microenvironment and its impact on cancer therapy. Frontiers in molecular biosciences, 6, 160.
39. Tam, S. Y., Wu, V. W., & Law, H. K. (2020). Hypoxia-induced epithelial-mesenchymal transition in cancers: HIF-1α and beyond. Frontiers in oncology, 10, 486.
40. Truong, L. H., &Pauklin, S. (2021). Pancreatic cancer microenvironment and cellular composition: current understandings and therapeutic approaches. Cancers, 13(19), 5028.

41. Buruiană, A., Gheban, B. A., Gheban-Roșca, I. A., Georgiu, C., Crișan, D., &Crișan, M. (2024). The tumor stroma of squamous cell carcinoma: a complex environment that fuels cancer progression. Cancers, 16(9), 1727.
42. Anderson, E. M., Thomassian, S., Gong, J., Hendifar, A., &Osipov, A. (2021). Advances in pancreatic ductal adenocarcinoma treatment. Cancers, 13(21), 5510.
43. Desai, S. A., Patel, V. P., Bhosle, K. P., Nagare, S. D., &Thombare, K. C. (2025). The tumor microenvironment: shaping cancer progression and treatment response. Journal of Chemotherapy, 37(1), 15-44.
44. Taleb, M., Mohammadkhani, N., Bahreini, F., Ovais, M., &Nie, G. (2022). Modulation of tumor vasculature network: key strategies. Small Structures, 3(6), 2100164.
45. Qian, C., Liu, C., Liu, W., Zhou, R., & Zhao, L. (2023). Targeting vascular normalization: a promising strategy to improve immune–vascular crosstalk in cancer immunotherapy. Frontiers in immunology, 14, 1291530.
46. Wang, Z., Ye, Q., Yu, S., &Akhavan, B. (2023). Poly ethylene glycol (PEG)-based hydrogels for drug delivery in cancer therapy: a comprehensive review. Advanced healthcare materials, 12(18), 2300105.
47. Bruni, C., Campochiaro, C., & de Vries-Bouwstra, J. K. (2023). Interstitial lung disease: how should Therapeutics be implemented?. Rheumatic Disease Clinics, 49(2), 279-293.
48. Veettil, S. R. U., Hwang, D., Correia, J., Bartlett, M. D., & Schneider, I. C. (2021). Cancer cell migration in collagen-hyaluronan composite extracellular matrices. ActaBiomaterialia, 130, 183-198.
49. Panza, S., Malivindi, R., Caruso, A., Russo, U., Giordano, F., Győrffy, B., ...&Andò, S. (2021). Novel insights into the antagonistic effects of losartan against angiotensin II/AGTR1 signaling in glioblastoma cells. Cancers, 13(18), 4555.
50. Skorupan, N., Palestino Dominguez, M., Ricci, S. L., &Alewine, C. (2022). Clinical strategies targeting the tumor microenvironment of pancreatic ductal adenocarcinoma. Cancers, 14(17), 4209.
51. Huber, M., Brehm, C. U., Gress, T. M., Buchholz, M., AlashkarAlhamwe, B., Pogge von Strandmann, E., ...&Lauth, M. (2020). The immune microenvironment in pancreatic cancer. International journal of molecular sciences, 21(19), 7307.
52. Shebbo, S., Binothman, N., Darwaish, M., Niaz, H. A., Abdulal, R. H., Borjac, J., ...& Mahmoud, A. B. (2024). Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy. Frontiers in Immunology, 15, 1350208.
53. Gillette, C. M., Yette, G. A., Cramer, S. D., & Graham, L. S. (2023). Management of advanced prostate cancer in the precision oncology era. Cancers, 15(9), 2552.
54. Gaebler, D., Hachey, S. J., & Hughes, C. C. (2024). Microphysiological systems as models for immunologically 'cold'tumors. Frontiers in Cell and Developmental Biology, 12, 1389012.
55. Vitorakis, N., Gargalionis, A. N., Papavassiliou, K. A., Adamopoulos, C., &Papavassiliou, A. G. (2024). Precision targeting strategies in pancreatic cancer: the role of tumor microenvironment. Cancers, 16(16), 2876.
56. Kozlova, N., Grossman, J. E., Iwanicki, M. P., &Muranen, T. (2020). The interplay of the extracellular matrix and stromal cells as a drug target in stroma-rich cancers. Trends in pharmacological sciences, 41(3), 183-198.
57. Principe, D. R. (2024). Transforming Growth Factor β Signaling in the Pancreatic Tumor

Microenvironment (Doctoral dissertation, University of Illinois at Chicago).
58. Cordani, M., Walerych, D., Silva, J.L., Timofeev, O. and Cirone, M. eds., 2021. Mutant p53 in Cancer Progression and Personalized Therapeutic Treatments. Frontiers Media SA.
59. Elenbaas, J.S., 2024. Characterizing the Causal Role of SVEP1 in Human Disease (Doctoral dissertation, Washington University in St. Louis).
60. Sessions, O. and Session, R., 2025. Study of Obesity: UK Congress on Obesity 2025. management.
61. López-Cortés, R., S. Vázquez-Estévez, J. Á. Fernández, and C. Núñez. Proteomics as a Complementary Technique to Characterize Bladder Cancer. Cancers 2021, 13, 5537. 2021.
62. Seyhan, Attila A. "Circulating liquid biopsy biomarkers in glioblastoma: advances and challenges." International Journal of Molecular Sciences 25, no. 14 (2024): 7974.
63. Reeves, E., 2022. Monitoring tumour response to extracellular matrix modulation with multiparametric MRI.
64. Offringa, Rienk, Lisa Kötzner, Bayard Huck, and Klaus Urbahns. "The expanding role for small molecules in immuno-oncology." Nature Reviews Drug Discovery 21, no. 11 (2022): 821-840.
65. Cortiana, V., Abbas, R. H., Chorya, H., Gambill, J., Mahendru, D., Park, C. H., &Leyfman, Y. (2024). Personalized medicine in pancreatic cancer: the promise of biomarkers and molecular targeting with dr. Michael J. Pishvaian. Cancers, 16(13), 2329.
66. Edwards, P., Kang, B. W., & Chau, I. (2021). Targeting the stroma in the management of pancreatic cancer. Frontiers in Oncology, 11, 691185.
67. Carlos-Escalante, J. A., de Jesus-Sanchez, M., Rivas-Castro, A., Pichardo-Rojas, P. S., Arce, C., &Wegman-Ostrosky, T. (2021). The use of antihypertensive drugs as coadjuvant therapy in cancer. Frontiers in oncology, 11, 660943.
68. Nair, Nitya, et al. "Single-cell immune competency signatures associate with survival in phase II GVAX and CRS-207 randomized studies in patients with metastatic pancreatic cancer." Cancer immunology research 8.5 (2020): 609-617.
69. Abdou, Y., Pandey, M., Sarma, M., Shah, S., Baron, J., &Ernstoff, M. S. (2020). Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies. British journal of clinical pharmacology, 86(9), 1690-1702.
70. Moreira, R., Granja, A., Pinheiro, M. and Reis, S., 2021. Nanomedicine interventions in clinical trials for the treatment of metastatic breast cancer. Applied Sciences, 11(4), p.1624.
71. Halbrook CJ, Lyssiotis CA, di Magliano MP, Maitra A. Pancreatic cancer: advances and challenges. Cell. 2023 Apr 13;186(8):1729-54.
72. Thierry, K. (2023). Rôle du compartiment stromal et des macrophages dans le cancer du pancréas (Doctoral dissertation, Université Claude Bernard-Lyon I).
73. Agur, Z., Elishmereni, M., Foryś, U., &Kogan, Y. (2020). Accelerating the development of personalized cancer immunotherapy by integrating molecular patients' profiles with dynamic mathematical models. Clinical Pharmacology & Therapeutics, 108(3), 515-527.
74. Patras, L., Paul, D., &Matei, I. R. (2023). Weaving the nest: extracellular matrix roles in pre-metastatic niche formation. Frontiers in oncology, 13, 1163786.

75. Sahu, R. K. (Ed.). (2023). Brain Tumor Targeting Drug Delivery Systems: Advanced Nanoscience for Theranostics Applications. Bentham Science Publishers.
76. Neophytou, C. M., Panagi, M., Stylianopoulos, T., &Papageorgis, P. (2021). The role of tumor microenvironment in cancer metastasis: molecular mechanisms and therapeutic opportunities. Cancers, 13(9), 2053.

HOW TO CITE: Sukhpreet Kaur, Gurpreet Kaur, Tanveer Ahmad, Nisha, Targeting Tumor Microenvironment in Pancreatic Cancer: A Translational Approach, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 5, 242-256. https://doi.org/10.5281/zenodo.19983775